Associations between early tumor shrinkage/depth of response and survival from the ARCAD database
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Early tumor shrinkage and depth of response are key prognostic indicators for metastatic colorectal cancer (CRC). These metrics predict outcomes for patients receiving anti-EGFR antibodies or bevacizumab, guiding treatment strategies.
Area Of Science
- Oncology
- Clinical Research
- Cancer Therapeutics
Background
- Prognostic significance of early tumor shrinkage and depth of response in metastatic colorectal cancer (CRC) is emerging.
- Association of these indicators with survival outcomes in patients receiving anti-EGFR antibodies or bevacizumab is not fully understood.
Purpose Of The Study
- To investigate the prognostic value of early tumor shrinkage and depth of response.
- To evaluate their impact on overall survival, progression-free survival (PFS), and postprogression survival.
- To compare outcomes in patients treated with anti-EGFR antibodies versus bevacizumab.
Main Methods
- Analysis of 3219 treatment-naive RAS wild-type metastatic CRC patients from 8 randomized studies.
- Definition of early tumor shrinkage as ≥20% tumor reduction at 8±2 weeks.
- Assessment of depth of response by maximum tumor shrinkage at nadir.
- Use of Cox regression models to assess associations with survival outcomes, adjusting for confounders.
Main Results
- Early tumor shrinkage and depth of response significantly stratified overall survival, PFS, and postprogression survival.
- Early tumor shrinkage positivity correlated with improved survival in both anti-EGFR and bevacizumab therapies.
- Optimal depth of response cutoffs identified: 0.55 for anti-EGFR and 0.47 for bevacizumab, predicting ~32 months median overall survival.
Conclusions
- Early tumor shrinkage and depth of response are valuable prognostic markers in RAS wild-type metastatic CRC.
- These markers are particularly relevant for patients treated with anti-EGFR antibodies.
- Findings support the use of these indicators for guiding treatment strategies and improving patient outcomes.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...